Published in Medical Letter on the CDC and FDA, March 22nd, 2009
Led by industry expert, Max Colao, Executive Director, Oncology Marketing, Amgen, the discussion will take the audience through the implications of the new FDAAA guidelines on oncology launch strategy.
Drawing key learnings from, Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding, Max and other leading industry...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA